TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

HOUSTON--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker ...

这项研究突破标志着诱导多能干细胞向免疫细胞疗法的规模化和更高可及性迈出关键一步，即已能实现两种核心免疫细胞的可控培育及比例精准调控，为探索辅助性 T 细胞在癌症治疗中的作用及开发新型调节性 T 细胞疗法奠定基础。

Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...

AI-Focused Genomics Company Advancing De-Aging Science Collaborates with Leading iPS Cell Manufacturing and Research ...